Endo’s Generics Add $30m Due To COVID-19 Impact
Company Sees $75m Overall Growth In Q1 From Coronavirus Demand
Despite reporting 14% growth in the first quarter of 2020, Endo has forecast a downturn in the second quarter and has withdrawn its full-year financial guidance due to uncertainty regarding the continued impact of the coronavirus pandemic.
